No abstract

Background Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated with this drug may develop candidiasis. This report presents a case of atypical oral candidiasis occurring during targeted drug immunotherapy with an interleukin 17 (IL-17) inhibitor (secukinumab), with the aim of emphasisinge the necessity of periodical oral health assessment and monitoring. It provides a rational clinical approach to therapeutic protocol in the treatment of side effects associated with novel medications for autoimmune diseases. Case presentation Symptomatic tongue lesions were observed in a 50-year-old female patient on a monthly systemic treatment of 300 mg of secukinumab, which appeared after 60 days of using the medication. Two inconclusive biopsies and an unsuccessful application of oral corticosteroids made the diagnostic process challenging. Papillae on the back of the tongue were atrophied, forming a well-defined erythema and white non-detachable plaques on the lateral border of the tongue. Cytopathological and histopathological exam results were compatible with a diagnosis of oral candidiasis. Topical antifungal medication led to subsequent regression of the tongue lesions. During asymptomatic period and follow up for 7 months, a reduced monthly dose 150 mg of secukinumab was administered. Conclusions Patients undergoing treatment with IL-17 blockers, such as secukinumab, should be carefully monitored in order to avoid oral side effects resulting from the use of this medication.

Aims: Looking for scientific support with an updated review about herbal medicines usage in dentistry for clinical application, reinforcing the potential of phytotherapics to treat oral disorders and the need for new studies on the topic. Material and Methods: The literature search was performed combining “phytotherapy” and “dentistry” in the PubMed, MEDLINE, BBO, LILACS and SciELO databases, covering the period from January 2017 to March 2020. The data extracted were: Alteration/oral disease, gender, age, number of participants, herbal medicine used, drug function and results. Results: were selected 24 papers that employed different plants, such as Tulsi, Aloe vera, citronella, turmeric, propolis and cloves. The results found are promising and show the anti-inflammatory, analgesic, antibacterial, antioxidant, antifungal, antiviral and tranquilizer action of herbal drugs, and their use for treating burning mouth syndrome, oral submucous fibrosis, xerostomia and halitosis. Conclusion: despite the therapeutic activities of herbal medicines, additional studies with larger sample size and scientific rigor are necessary to prove their benefits for treating oral diseases.

No abstract

Resumo: Objetivo: esta revisão sistemática da literatura teve como objetivo encontrar dados que esclarecessem a controvérsia sobre associação entre língua geográfica e doenças atópicas/atopia, enfatizando a correlação entre estas condições. Material e Métodos: os dados avaliados incluíram idade, sexo, história familiar e pessoal de atopia, prevalência de língua geográfica, níveis séricos de imunoglobulina E (IgE) e testes cutâneos. Resultados: 08 artigos foram selecionados e lidos na íntrega e as informações encontradas utilizadas neste estudo. Durante a revisão, houve dificuldade na padronização dos achados devido à falta de detalhes no diagnóstico de atopia e língua geográfica; e falta de análise individualizada das condições atópicas: asma, rinite ou dermatite atópica. Limitação: baixo número de publicações sobre o tema. Conclusão: com base na literatura, um número maior de dados são necessários para confirmação da relação entre língua geográfica, doenças atópicas/atopia, além de outros estudos com tamanho amostral maior, diagnóstico detalhado de atopia/ doenças atópicas e língua geográfica e dosagem sérica IgE determinada simultaneamente ao exame bucal e testes cutâneos.